Trial Profile
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Trial to Investigate the Efficacy, Tolerability, Safety and Pharmacokinetics of TMC435 as Part of a Treatment Regimen Including Peginterferon Alfa-2a and Ribavirin In Treatment-Naive Genotype 1 Hepatitis C-Infected Subjects
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs Simeprevir (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms PILLAR
- Sponsors Janssen R&D Ireland
- 26 Apr 2013 Results presented at the 48th Annual Meeting of the European Association for the Study of the Liver.
- 08 Apr 2013 Results will be presented at The International Liver Congress 2013 of the European Association for the Study of the Liver (EASL), according to a Janssen R&D Ireland media release.
- 01 Oct 2012 Results were presented at the 63nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) according to a Medivir media release..